2026. Reduced Dosing Frequency With Tralokinumab Provides Sustained Improvements in Symptoms and Quality of Life Up to 1 Year in Adults With Moderate-to-Severe AD. SKIN The Journal of Cutaneous Medicine. 10, 2 (Mar. 2026), s731. DOI:https://doi.org/10.25251/26swpe94.